首页> 外文期刊>Pharmacological reviews >International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli
【24h】

International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli

机译:国际基础和临床药理学联盟。 XCIX。血管紧张素受体:病理生理性血管紧张素能刺激的解释器

获取原文
           

摘要

The renin angiotensin system (RAS) produced hormone peptides regulate many vital body functions. Dysfunctional signaling by receptors for RAS peptides leads to pathologic states. Nearly half of humanity today would likely benefit from modern drugs targeting these receptors. The receptors for RAS peptides consist of three G-protein-coupled receptors-the angiotensin II type 1 receptor (AT(1) receptor), the angiotensin II type 2 receptor (AT(2) receptor), the MAS receptor-and a type II trans-membrane zinc protein-the candidate angiotensin IV receptor (AngIV binding site). The prorenin receptor is a relatively new contender for consideration, but is not included here because the role of prorenin receptor as an independent endocrine mediator is presently unclear. The full spectrum of biologic characteristics of these receptors is still evolving, but there is evidence establishing unique roles of each receptor in cardiovascular, hemodynamic, neurologic, renal, and endothelial functions, as well as in cell proliferation, survival, matrix-cell interaction, and inflammation. Therapeutic agents targeted to these receptors are either in active use in clinical intervention of major common diseases or under evaluation for re-purposing in many other disorders. Broad-spectrum influence these receptors produce in complex pathophysiological context in our body highlights their role as precise interpreters of distinctive angiotensinergic peptide cues. This review article summarizes findings published in the last 15 years on the structure, pharmacology, signaling, physiology, and disease states related to angiotensin receptors. We also discuss the challenges the pharmacologist presently faces in formally accepting newer members as established angiotensin receptors and emphasize necessary future developments.
机译:肾素血管紧张素系统(RAS)产生的激素肽调节许多重要的身体功能。 RAS肽受体的信号传导异常会导致病理状态。今天,将近一半的人类可能会受益于靶向这些受体的现代药物。 RAS肽的受体由三种G蛋白偶联受体组成:血管紧张素II 1型受体(AT(1)受体),血管紧张素II 2型受体(AT(2)受体),MAS受体和一种II跨膜锌蛋白-候选血管紧张素IV受体(AngIV结合位点)。肾上腺素受体是一个相对较新的考虑因素,但由于目前还不清楚,肾上腺素受体作为独立的内分泌介质的作用尚不明确。这些受体的生物学特性仍在不断发展,但是有证据表明每种受体在心血管,血液动力学,神经,肾和内皮功能以及细胞增殖,存活,基质-细胞相互作用,和炎症。靶向这些受体的治疗剂正在积极用于主要常见疾病的临床干预中,或者正在评估其在许多其他疾病中的重新用途。这些受体在我们体内复杂的病理生理环境中产生的广谱影响突出了它们作为独特的血管紧张素肽提示的精确解释者的作用。这篇综述文章总结了过去15年中有关血管紧张素受体的结构,药理学,信号传导,生理学和疾病状态的发现。我们还将讨论药师目前在正式接受较新成员作为已建立的血管紧张素受体方面面临的挑战,并强调未来的必要发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号